Skip to the page

Data / Drug companies / Sanofi-Aventis U.S. LLC

Sanofi-Aventis U.S. LLC: 16 products in the FDA NDC directory, labeler code 0075

Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).

Sanofi-Aventis U.S. LLC (labeler code 0075) lists 16 products in the FDA National Drug Code Directory, covering 1 finished drug by generic name. By type: 16 prescription drugs. Its main marketing category is new drug applications (NDA). The newest product started marketing on March 29, 1993.

The request: Watch Sanofi-Aventis U.S. LLC (FDA labeler code 0075): each new product listing and each discontinued product. $10 of work on sign-up, no card.

SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.

Labeler code
0075
Products in commercial distribution
16
Packages
16
Finished drugs by generic name
1
Prescription products
16
Over the counter products
0
Flagged as original packager
16 of 16 products that carry the flag
Started marketing in the last 12 months
0
Earliest marketing start
March 29, 1993
openFDA record search
api.fda.gov

Products by marketing category

Share of the company's products in commercial distribution.

Marketing categoryProductsShare
New drug applications (NDA)16100%

Products by type

TypeProductsShare
Prescription drugs16100%

Drugs it lists

Finished drugs by generic name, with how many companies list each.

DrugProductsCompanies listing it
Enoxaparin sodium1618

Dosage forms

Dosage formProductsShare
Injection16100%

Pharmacologic classes

FDA established pharmacologic classes of its products.

Newest products

By marketing start date.

ProductProduct NDCDosage formMarketing categoryMarketing start
Lovenox0075-8030InjectionNew drug applications (NDA)March 29, 1993
Lovenox0075-8025InjectionNew drug applications (NDA)March 29, 1993
Lovenox0075-8022InjectionNew drug applications (NDA)March 29, 1993
Lovenox0075-8020InjectionNew drug applications (NDA)March 29, 1993
Lovenox0075-8018InjectionNew drug applications (NDA)March 29, 1993
Lovenox0075-8016InjectionNew drug applications (NDA)March 29, 1993
Lovenox0075-8014InjectionNew drug applications (NDA)March 29, 1993
Lovenox0075-8013InjectionNew drug applications (NDA)March 29, 1993
Lovenox0075-2915InjectionNew drug applications (NDA)March 29, 1993
Lovenox0075-2912InjectionNew drug applications (NDA)March 29, 1993
Lovenox0075-0626InjectionNew drug applications (NDA)March 29, 1993
Lovenox0075-0624InjectionNew drug applications (NDA)March 29, 1993
Lovenox0075-0623InjectionNew drug applications (NDA)March 29, 1993
Lovenox0075-0622InjectionNew drug applications (NDA)March 29, 1993
Lovenox0075-0621InjectionNew drug applications (NDA)March 29, 1993
Lovenox0075-0620InjectionNew drug applications (NDA)March 29, 1993

CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.